H1155 Cell Line Derived Xenograft
The H1155 xenograft model is derived from the NCI-H1155 cell line, a human non-small cell lung cancer (NSCLC) subtype classified as lung adenocarcinoma. This model is particularly relevant for studying oncogenic alterations in receptor tyrosine kinase signaling and for evaluating targeted therapies. It is typically implanted in immunodeficient mice, where it forms moderately growing tumors with characteristics representative of the original patient tumor, including epithelial morphology and dependence on key oncogenic drivers. Gene expression analysis of H1155 tumors reveals high levels of EGFR expression, which is a defining feature of this model, making it suitable for studying EGFR-targeted inhibitors. The model also exhibits activation of downstream signaling pathways, including PI3K/AKT and MAPK/ERK, contributing to tumor cell survival and proliferation. Additionally, H1155 expresses markers associated with epithelial differentiation, with relatively lower expression of mesenchymal markers, indicating limited epithelial-mesenchymal transition (EMT) activity. Mutational profiling of H1155 identifies a key EGFR exon 19 deletion (E746_A750del), a well-characterized oncogenic driver mutation that leads to constitutive EGFR activation and sensitivity to tyrosine kinase inhibitors (TKIs). The model also harbors a TP53 mutation (R273H), which disrupts normal tumor suppressor function and enhances tumor cell survival. These molecular alterations make the H1155 xenograft model a valuable platform for investigating EGFR-targeted therapies, resistance mechanisms, and combination treatment strategies in lung adenocarcinoma.
NCI-H1155 xenograft is a research model in which H1155 cancer cells are transplanted into immunodeficient mice, to study tumor growth, response to treatment, and other aspects of cancer biology. Xenograft models are often used in nonclinical research to evaluate the effectiveness of new cancer therapies before testing them in humans. Subcutaneous tumor implants remain the key tumor models due to the ability to easily follow non-invasively. Also, it has yet to be shown that other models (e.g. orthotopic tumor models or genetically engineered mouse models) would lead to the discovery of drugs missed by subcutaneous models. The H1155 CDX model complements this idea with preclinical research such as treatment of gefitinib or erlotinib in combination with OSU-03012 (a celecoxib-derived antitumor agent) to overcome EGFR inhibitor-resistance.
| H1155 | PTEN(mut), KRAS(mut), p53(mut) |
| Origin | Lung |
| Disease | Carcinoma, large cell |
| Metastatic Models (Lung) | A549 |
| Non-Metastatic Models (Lung) | Calu-3, Calu-6, H1155, H460, LL/2, NCI-H1975, NCI-H226 |
Get Instant Quote for
H1155 Xenograft Model
What is a Xenograft?
Development of an anti-cancer therapeutic requires intense, well planned studies that follow a streamlined path for success. Primary studies are performed in an in vitro setting that allows for high throughput screening and analysis of multiple compounds of interest. This method enables a focused compound screening approach of multiple cell lines within a specific cancer type, or a divergent approach across a broad range of cancer types. Ultimately, in vitro screening results need to be confirmed in an animal model due to in vitro inadequacies of cells cultured on plastic, as this method is far removed from the microenvironment of a tumor.
Why use Xenograft Models?
Cell line derived xenograft (CDX) models or patient derived tumor xenograft (PDX) models enable a larger realm of parameters to be studied not capable with in vitro studies. The complete animal system model expands the scope of studies available to include the effect of test compounds on pharmacokinetics (PK), pharmacodynamics (PD), alternate routes of delivery, inhibition of metastasis, CBCs, dosing regimens, dose levels, etc. However, one of the major drawbacks of CDX and PDX models is that the human cancer cell lines or human patient derived tumors must be implanted in immunocompromised mice in order to bypass the graft versus host rejection by the animal. With the increasing focus of the immune systems role in the recognition and elimination of tumor cells (i.e. immunotherapy), major consideration must be taken into account during experimental concept design of the limitation of checkpoint inhibitors or desired immune response involvement in tumor efficacy. Similarly, any tumor regression after treatment with a test compound in these models will not exhibit the potential complement cascade or innate immune response of the injected therapeutic in humans.
What we offer?
Our in vivo xenograft service department evaluates the efficacy of preclinical and clinical cancer therapeutics utilizing more than 50 validated immunocompromised xenograft mouse models. The value of utilizing our xenograft service department is highlighted by the ability to completely characterize the efficacy, dose regimen, dose levels and optimal combination ratios of lead compounds for cancer, obesity, diabetes, infections and immunology research.
During the design and execution of the xenograft study, our scientists will communicate with and assist the client’s decisions regarding these details:
- Study Group Formation: classification of mice by body weight, tumor size or other parameters
- Cancer Cell Line: use of in-house cell lines or utilization of customer-provided cell lines
- Tumor Implantation: intraperitoneal, subcutaneous, submuscular or intravenous
- Test Compound Administration: intraperitoneal, intravenous, tail vein, subcutaneous, topical, oral gavage, osmotic pumps or subcutaneous drug pellets
- Sample Collection: Tumors/tissues can be fixed in 10% NBF, frozen in liquid N2 or stabilized in RNAlater; blood chemistry analysis can be performed throughout the in-life portion of study
Vivarium
Our vivarium is designed such that it enables cost-effective and first-rate preclinical effectiveness testing services. All animal handling and maintenance is regulated following IACUC guidelines. Our facility consists of the following:
- IACUC-regulated and GLP-compliant
- Controlled, limited access lab areas
- Disposable cages
- Sterile food and water
- SPF (specific pathogen-free) animals to guarantee pathogens do not interfere with the experiment
- Established animal handling and micro-injection equipment systems, including an animal health observation program
- All studies follow pre-approved SOPs
Our staff understands that each proposed study design is unique and customized to the client’s needs. We also recognize the importance of the delivered results as being confidential, highly reproducible and that 100% of the intellectual property (IP) is owned by the client.
In order to receive a quote for your xenograft study, email us the specific details listed below in order to efficiently begin the study quote process:
- Cancer cell line(s) used in the study
- Number (n=) of animals in each study group
- Number of study groups and control groups
- Tumor implantation route
- Administration route of test compound
- Species of immunocompromised mouse (e.g. NOD/SCID, athymic Nude)
- Treatment and dose schedule
- Study endpoint and analysis (e.g. tumor growth delay, PK/PD, survival, toxicity, drug combinations)
- Samples collected: tumor and tissues to be collected, including storage condition (e.g. snap frozen, RNAlater, 10% NBF, nucleic acid isolation)